BioSpace News Archive

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001).

Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan M.D., Ph.D., to its Board of Directors.

Ardelyx, Inc. announced that leading proxy advisory firms Institutional Shareholder Services Inc. and Glass Lewis & Co have recommended that Ardelyx stockholders vote “FOR” the Company’s proposal to amend the Company’s certificate of incorporation to increase Ardelyx’s authorized shares of common stock from 300 million to 500 million shares.

Galderma announced today the U.S. Food and Drug Administration (FDA) approved Restylane® Eyelight for the treatment of undereye hollows, also known as dark shadows, in adults over the age of 21.

Cardiff Oncology, Inc. announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 7-9, 2023.

Waters Corporation and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics.

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.

GE HealthCare (Nasdaq: GEHC) today announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based technology designed to dramatically accelerate image acquisition in magnetic resonance imaging (MRI).

OrsoBio, Inc. today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.